Summary
The National Institutes of Health (NIH) is soliciting applications under the Blueprint Neurotherapeutics Network (BPN) program to support small molecule drug discovery and development targeting disorders of the nervous system. The funding mechanism is a UG3/UH3 phased cooperative agreement, with clinical trials listed as optional. The program aims to advance novel small molecule therapeutics from early discovery through development stages for neurological and nervous system conditions. This is a federal grant opportunity posted on Grants.gov, open to eligible research institutions and organizations.
